Hong Kong, 19 March 2026—China Resources Pharmaceutical Group Limited (CR Pharma, 03320.HK) disclosed key audited figures for its 28.05%-owned subsidiary KPC Pharmaceuticals, Inc. (Shanghai: 600422) for the year ended 31 December 2025. The data were prepared under PRC GAAP and audited by KPC’s external auditor.

Financial highlights for FY 2025 (YoY comparisons versus FY 2024):

1. Revenue fell 21.74% to RMB 6.58 billion, reflecting a contraction from RMB 8.40 billion.

2. Net profit attributable to KPC shareholders declined 46.00% to RMB 0.35 billion. Basic and diluted EPS both dropped to RMB 0.46, down 46.51%.

3. Excluding extraordinary gains and losses, net profit slid 74.45% to RMB 0.11 billion, signaling a sharp deterioration in core profitability.

4. Weighted average return on equity decreased by 2.94 percentage points to 6.58%.

5. Net cash flow from operating activities shrank 64.21% to RMB 0.29 billion, compared with RMB 0.81 billion in the prior year.

Balance-sheet position as at 31 December 2025:

• Total assets stood at RMB 11.77 billion, down 6.64% from RMB 12.61 billion a year earlier. • Net assets attributable to KPC shareholders inched up 2.07% to RMB 5.36 billion.

Dividend proposal:

KPC’s board recommends a cash dividend of RMB 1.80 for every 10 shares (equivalent to RMB 0.18 per share, tax inclusive), subject to approval at the 2025 annual general meeting and based on the total share capital on the record date.

The disclosed figures pertain solely to KPC and do not represent the consolidated performance of CR Pharma. Investors are advised to review KPC’s full annual report, available on the Shanghai Stock Exchange website, for additional context and to exercise caution when dealing in CR Pharma securities.